Results 151 to 160 of about 191,618 (313)

Statistical models used for GWAS - Lecture 7 H3ABioNet 2018 GWAS Lecture series

open access: yes, 2018
Statistical models used for GWAS The seventh and last lecture of the
Cheikh Loucoubar (279995)
core   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba   +2 more
wiley   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

open access: yesBMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang   +8 more
wiley   +1 more source

Digesting GWAS [PDF]

open access: yesCellular and Molecular Gastroenterology and Hepatology, 2016
openaire   +3 more sources

GWAS of varying phenotypic scales.

open access: yes, 2013
GWAS have primarily been used to characterize disease-related characteristics in patient populations, but new approaches have expanded the phenotypes used in GWAS. “Clinical GWAS” search for associations between genetic differences (primarily in the form
Dennis C. Ko (198506)   +1 more
core   +1 more source

Increased Insulin Action, Glucose Metabolism and Muscle Function in Supervillin‐Knockout and Supervillin‐Mutant Mice

open access: yesCytoskeleton, EarlyView.
ABSTRACT We here describe mouse models with complementary homozygous Svil mutations. In skeletal muscle, Svil‐Mut mice express the Svil‐encoded N‐terminus fused to the βgal‐neo gene‐trap tag and lack the highly conserved archvillin C‐terminus; Svil‐KO mice lack expression of all known Svil‐encoded proteins; and Svil‐LoxP mice contain loxP sites for ...
Tara C. Smith   +9 more
wiley   +1 more source

GWAS Results, CCA

open access: yes, 2014
Results from GWAS of eigenvectors (CCAs) 1-5, after CCA of the bacterial and (separately) the fungal community. This tarball includes 'reports' (e.g. the top SNPs after GWAS), image files (manhattan plots), and the top GO-terms enriched in these GWAS ...
Vilhjálmsson, Bjarni   +21 more
core   +1 more source

Genomic Insights Into Risperidone Treatment Outcomes in Children and Adolescents: Experience From a Psychiatric Hospital Serving Rural Youth

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples   +10 more
wiley   +1 more source

The Language of Greenwashing: SDG Omission and Opportunity‐Oriented Environmental Tone as Alert Metrics in Green Bond Disclosures

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Green bonds play a central role in sustainable finance, yet concerns about greenwashing raise questions about the credibility of issuers' sustainability disclosures. Using dictionary‐based methods and domain‐specific BERT transformer models, this paper proposes two greenwashing alert metrics and investigates their performance by analyzing ...
Andrea Nicolodi   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy